Frank H. Laukien, Ph.D.

Board Member

Equibles does not estimate personal net worth.

Get an email with a short summary when Bruker Corp publishes a filing, an earnings call transcript or a press release.

About Frank H. Laukien, Ph.D.

Frank H. Laukien, Ph.D. is recorded as Board Member at Bruker Corp (BRKR) since May 29, 2025. Bruker Corp reported in an 8-K filed May 29, 2025 that Frank H. Laukien, Ph.D. was appointed Class I director, effective May 29, 2025. Frank H. Laukien, Ph.D. has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Bruker Corp on September 16, 2026. Bruker Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Bruker Corp includes Burkhard A. Prause (CEO), Frank Laukien (CEO), Gerald Herman (CFO) and 7 others.

“The following director nominees were elected to serve as Class I members of the Company’s board of directors, each to serve for a three-year term until the Company’s 2028 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified based on the following votes:”

Bruker Corp Form 8-K, filed May 29, 2025 · Read the filing

Frank H. Laukien, Ph.D. on recent calls

“I think we're in that inflection point where people are trying to understand biology much more deeply, disease biology, drug discovery, biomarkers that may play a role in diagnostics or MRD or whatever it may be.”

Chairman, Morgan Stanley 24th Annual Global Healthcare Conference · September 16, 2026

“While U.S. academic demand, tariff, and currency headwinds have continued to pressure our year-over-year results, results, we are pleased that our first quarter 26 financial performance came in well ahead of expectations.”

CEO, Bruker Corp Q1 FY2026 Earnings Call · May 6, 2026